Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Adults - 18 - 64
  • New Mexico
  • Farmington


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Capacity Builders Inc. Navajo Youth Builders Personal Responsibility Education Innovation Strategies Project
    NCT04180358
    Conditions:   Sexual Abstinence;   Responsible Sex
    Interventions:   Behavioral: Native STAND;   Behavioral: Regular Health/Physical Education Curriculum
    Sponsors:   Capacity Builders Inc.;   Mathematica Policy Research, Inc.;   Family and Youth Services Bureau
    Recruiting
  • An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
    NCT03817853
    Condition:   Advanced Follicular Lymphoma
    Interventions:   Drug: Obinutuzumab;   Drug: Bendamustine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone/Prednisolone/Methylprednisolone;   Drug: Vincristine
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • National Cardiogenic Shock Initiative
    NCT03677180
    Conditions:   Cardiogenic Shock;   Acute Myocardial Infarction;   STEMI - ST Elevation Myocardial Infarction;   NSTEMI - Non-ST Segment Elevation MI;   Heart Attack
    Intervention:  
    Sponsors:   Henry Ford Health System;   Abiomed Inc.;   Chiesi Farmaceutici S.p.A.
    Recruiting
  • A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
    NCT03412565
    Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Carfilzomib
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
    NCT03409614
    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: REGN2810;   Drug: REGN2810/chemo/ipi;   Other: Chemotherapy;   Drug: Placebo
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting
  • Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
    NCT03395197
    Condition:   mCRPC
    Interventions:   Drug: Talazoparib with enzalutamide;   Drug: Placebo with enzalutamide
    Sponsors:   Pfizer;   Astellas Pharma Inc
    Recruiting
  • Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
    NCT03307785
    Conditions:   Metastatic Cancer;   Advanced Cancer;   Solid Tumor;   Non Small Cell Lung Cancer Metastatic;   Non Small Cell Lung Cancer Stage IIIB;   Non Small Cell Lung Cancer
    Interventions:   Drug: Niraparib;   Drug: TSR-042;   Drug: Carboplatin-Paclitaxel;   Drug: Bevacizumab;   Drug: TSR-022;   Drug: Carboplatin Pemetrexed;   Drug: Carboplatin-Nab-Paclitaxel
    Sponsor:   Tesaro, Inc.
    Recruiting
  • A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
    NCT02817633
    Condition:   Advanced or Metastatic Solid Tumors
    Interventions:   Drug: TSR-022;   Drug: TSR-042, an anti-PD-1 antibody;   Drug: TSR-033, an anti-LAG-3 antibody
    Sponsor:   Tesaro, Inc.
    Recruiting
  • Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
    NCT02793583
    Conditions:   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202;   Drug: TGR-1202 + Ublituximab + Bendamustine
    Sponsor:   TG Therapeutics, Inc.
    Recruiting
  • A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
    NCT02715284
    Condition:   Advanced or Metastatic Solid Tumors
    Intervention:   Biological: dostarlimab
    Sponsor:   Tesaro, Inc.
    Recruiting
  • A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
    NCT02599324
    Conditions:   Metastatic Renal Cell Carcinoma;   Advanced Urothelial Carcinoma;   Advanced Gastric Adenocarcinoma;   Metastatic Colorectal Adenocarcinoma
    Interventions:   Drug: Ibrutinib;   Drug: Everolimus;   Drug: Docetaxel;   Drug: Paclitaxel;   Drug: Cetuximab;   Drug: Pembrolizumab
    Sponsor:   Pharmacyclics LLC.
    Recruiting
  • Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
    NCT02188368
    Condition:   Multiple Myeloma
    Interventions:   Drug: POM;   Drug: Steroids;   Drug: PLD;   Drug: CFZ;   Drug: BTZ;   Drug: CLA;   Drug: Other drugs;   Drug: CY
    Sponsors:   Oncotherapeutics;   Celgene Corporation
    Recruiting
  • My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
    NCT02091141
    Conditions:   Neoplasms;   Solid Tumors;   Biliary Cancer;   Salivary Cancer;   Bladder Cancer
    Interventions:   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Erlotinib;   Drug: Vemurafenib;   Drug: Cobimetinib;   Drug: Vismodegib;   Drug: Alectinib;   Drug: Atezolizumab
    Sponsor:   Genentech, Inc.
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC